ahlam1399
08-26-2016, 07:51 AM
Lung cancer doctors eye Merck?s Keytruda over Bristol?s Opdivo
(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=K5uis021Xcw:YgIKbUqfL_s:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=K5uis021Xcw:YgIKbUqfL_s:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/K5uis021Xcw
(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=K5uis021Xcw:YgIKbUqfL_s:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=K5uis021Xcw:YgIKbUqfL_s:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=K5uis021Xcw:YgIKbUqfL_s:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/K5uis021Xcw